

# VIVOMIXX<sup>®</sup> Literature

## Original Articles:

188) Kumar M, Kisson-Singh V, Leon Coria A, Moreau F, Chadee K. **The probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin deficient mice.** *Am J Physiol Gastrointest Liver Physiol.* 2016 Nov 17;ajpgi.00298.2016.

187) Warrack S, Ziegler M, Duster M, Panjekar P, Safdar N. **A Pilot Randomized Trial to Determine the Tolerability of a Probiotic in Patients Colonized with Vancomycin-Resistant Enterococcus.** *J Prob Health* 2016, 4:2.

186) Halkjaer SI, Nilas L, Carlsen EM, Cortes D, Halldórsson TI, Olsen SF, Pedersen AE, Krogfelt KA, Petersen AM. **Effects of probiotics (Vivomixx<sup>®</sup>) in obese pregnant women and their newborn: study protocol for a randomized controlled trial.** *Trials.* 2016 Oct 11;17(1):491.

185) Lorén V, Manyé J, Fuentes MC, Cabré E, Ojanguren I, Espadaler J. **Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis.** *Probiotics Antimicrob Proteins.* 2016 Nov 10

184) Krishnan M, Penrose HM, Shah NN, Marchelletta RR, McCole DF. **VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN- $\gamma$ -induced Intestinal Epithelial Barrier Defects.** *Inflamm Bowel Dis.* 2016 Dec;22(12):2811-2823.

183) Chung EJ, Do EJ, Kim SY, Cho EA, Kim DH, Pak S, Hwang SW, Lee HJ, Byeon JS, Ye BD, Yang DH, Park SH, Yang SK, Kim JH, Myung SJ. **Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice.** *Eur J Pharmacol.* 2016 Nov 12;794:1-7.

182) Baldassarre ME, Di Mauro A, Mastromarino P, Fanelli M, Martinelli D, Urbano F, Capobianco D, Laforgia N. **Administration of a Multi-Strain Probiotic Product to Women in the Perinatal Period Differentially Affects the Breast Milk Cytokine Profile and May Have Beneficial Effects on Neonatal Gastrointestinal Functional Symptoms. A Randomized Clinical Trial.** *Nutrients* 2016, 8(11), 677; doi:10.3390/nu8110677.

181) Kigerl K, Hall J, Wang L, Mo X, Yu Z, Popovich P. **Gut dysbiosis impairs recovery after spinal cord injury.** *J. Exp. Med.* DOI: 10.1084/jem.20151345 | Published October 17, 2016.

180) Do EJ, Hwang SW, Kim SY, Ryu YM, Cho EA, Chung EJ, Park S, Lee HJ, Byeon JS, Ye BD, Yang DH, Park SH, Yang SK, Kim JH, Myung SJ. **Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by Balsalazide and VSL#3.** *J Gastroenterol Hepatol.* 2016 Aug;31(8):1453-61.

179) Scagnolari C, Corano Scheri G, Selvaggi C, Schietroma I, Fard N, Mastrangelo A, Giustini N, Serafino S, Pinacchio C, Pavone P, Fanello G, Ceccarelli G, Vullo V, d'Ettore G. **Probiotics**

**Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study.** *Int. J. Mol. Sci.* 2016, 17(10), 1639.

178) Hümeýra Unsal H, Unsal C, Uner AG, Koç Yildirim E, Ekici M, Balkaya M, Belge F. **The Effects of Swimming Exercise and Probiotic VSL#3 on Zonulin and Some Inflammatory and Oxidative Parameters in Rats.** *Kafkas Univ Vet Fak Derg* x (x): xxx-xxx, 2016 DOI: 10.9775/kvfd.2016.15949

177) Grossi E, Melli S, Dunca D, Terruzzi V. **Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics.** *SAGE Open Med Case Rep.* 2016 Aug 26;4:2050313X16666231.

176) Chan YK, El-Nezami H, Chen Y, Kinnunen K, Kirjavainen PV. **Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(-/-) mice.** *AMB Express.* 2016 Dec;6(1):61.

175) Jafarnejad S, Saremi S, Jafarnejad F, Arab A. **Effects of a Multispecies Probiotic Mixture on Glycemic Control and Inflammatory Status in Women with Gestational Diabetes: A Randomized Controlled Clinical Trial.** *J Nutr Metab.* 2016;2016:5190846.

174) Ortiz AM., Klase ZA., Di Napoli SR., Vujkovic-Cvijin I., Carmack K., Perkins MR., Calantone N, Vinton CL, Riddick NE, Gallagher J, Klatt NR, McCune JM, Estes JD, Paiardini M, Brenchley JM. **L-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques.** *Mucosal Immunol.* 2016 Mar;9(2):458-67.

173) Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, Darby TM, Weitzmann MN, Mulle JG, Gewirtz AT, Jones RM, Pacifici R. **Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics.** *J Clin Invest.* 2016 Apr 25.pii:86062. doi: 0.1172/JCI86062.

172) Manuzak JA., Hensley-McBain T., Zevin AS., Miller C., Cubas R., Agricola B., Gile J., Richert-Spuhler L., Patilea G., Estes JD., Langevin S., Reeves RK., Haddad EK., Klatt NR. **Enhancement of Microbiota in Healthy Macaques Results in Beneficial Modulation of Mucosal and Systemic Immune Function.** *J Immunol.* 2016 Mar 1;196(5):2401-9.

171) Brown K., Godovannyi A., Ma C., Zhang Y., Ahmadi-Vand Z., Dai C., Gorzelak MA., Chan Y., Chan JM., Lochner A., Dutz JP., Vallance BA., Gibson DL. **Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice.** *The ISME Journal* 2016 Feb; 10(2):321-32

170) Morampudi V., Dalwadi U., Bhinder G., Sham HP., Gill SK., Chan J., Bergstrom KS., Huang T., Ma C., Jacobson K., Gibson DL., Vallance BA. **The goblet cell-derived mediator RELM-β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis.** *Mucosal Immunol.* 2016 Sep;9(5):1218-33.

169) Selwyn F., Cheng S., Klaassen C., Cui J. **Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics.** *Drug Metab Dispos* 2016 Feb; 44:262–274.

- 168) Dolpady J., Sorini C., Di Pietro C., Caputo A., Ferrarese R., Saita D., De Simone C., Clementi M., Canducci F., Falcone M. **Oral probiotic VSL#3 prevents T1D by modulating microbiota and inducing a Indoleamine 2,3-dioxygenase (IDO)-enriched tolerogenic intestinal environment.** *Journal of Diabetes Research* Volume 2016, Article ID 7569431, 12 pages.
- 167) Ostan R., Béné MC., Spazzafumo L., Pinto A., Donini LM., Pryen F., Charrouf Z., Valentini L., Lochs H., Bourdel-Marchasson I., Blanc-Bisson C., Buccolini F., Brigidi P., Franceschi C., d'Alessio PA. **Impact of diet and nutraceutical supplementation on inflammation in elderly people. Results from the RISTOMED study, an open-label randomized control trial.** *Clin Nutr.* 2016 Aug;35(4):812-8.
- 166) Sánchez E., Nieto JC., Boullosa A., Vidal S., Sancho FJ., Rossi G., Sancho-Bru P., Oms R., Mirelis B., Juárez C., Guarner C., Soriano G. **VSL#3 Probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis.** *Liver Int.* 2015 Mar;35(3):735-45
- 165) Sang LX., Chang B., Wang BY., Liu WX., Jiang M. **Live and heat-killed probiotic: effects on chronic experimental colitis induced by dextran sulfate sodium (DSS) in rats.** *Int J Clin Exp Med.* 2015 Nov 15; 8(11):20072-8.
- 164) Boutagy NE., Neilson AP., Osterberg KL., Smithson AT., Englund TR., Davy BM., Hulver MW., Davy KP. **Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet.** *Obesity (Silver Spring).* 2015 Dec;23(12):2357-63.
- 163) Osterberg KL.,<sup>2</sup> Boutagy NE., McMillan RP., Stevens JR., Frisard MI., Kavanaugh JW., Davy BM., Davy KP., Hulver MW. **Probiotic supplementation attenuates increases in body mass and fat mass during high-fat diet in healthy young adults.** *Obesity (Silver Spring).* 2015 Dec;23(12):2364-70.
- 162) D'Mello C., Ronaghan N., Zaheer R., Dickey M., Le T., MacNaughton W., Surette M., Swain M. **Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication between the Peripheral Immune System and the Brain.** *The Journal of Neuroscience* 2015 July; 35(30): 10821-10830.
- 161) Sinha A., Gupta S., Chellani H., Maliye C., Kumari V., Arya S., Garg BS., Gaur S., Gaiind R., Deotale V., Taywade M., Prasad MS., Thavraj V., Mukherjee A., Roy M. **Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial.** *BMJ Open* 2015 10;5(7):e006564.
- 160) Man A.L., Bertelli E., Rentini S., Regoli M., Briars G., Marini M., Watson AJ., Nicoletti C. **Age-associated modifications of intestinal permeability and innate immunity in human small intestine.** *Clin Sci (Lond).* 2015 Oct;129 (7):515-27
- 159) Mariman R., Tielen F., Koning F., Nagelkerken L. **The Probiotic Mixture VSL#3 Has Differential Effects on Intestinal Immune Parameters in Healthy Female BALB/c and C57BL/6 Mice.** *J Nutr.* 2015 Jun; 145(6):1354-61.

158) Miccheli A., Capuani G., Marini F., Tomassini A., Praticò G., Ceccarelli S., Gnani D., Baviera G., Alisi A., Putignani L., Nobili V. **Urinary H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment.** *International Journal of Obesity*, 2015 Jul; 39(7):1118-25

157) Mastromarino P., Capobianco D., Miccheli A., Praticò G., Campagna G., Laforgia N., Capursi T., Baldassarre E. **Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery.** *Pharmacol Res.* 2015 May-Jun;95-96:63-70

156) Talero E., Bolivar S., Román J., Alcaide A., Fiorucci S., Motilva V. **Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3.** *Inflamm Bowel Dis* 2015 May;21(5):1027-37.

155) Souza D., Senchenkova E., Russell J., Granger D. **MyD88 Mediates the Protective Effects of Probiotics Against the Arteriolar Thrombosis and Leukocyte Recruitment Associated with Experimental Colitis.** *Inflamm Bowel Dis.* 2015 Apr;21(4):888-900

154) Kim S., Choi S., Park K., Park M., Shin J., Lee T., Jung K., Koo H., Myung S., and Constipation Research group of Korean Society of Neurogastroenterology and Motility. **Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation.** *J Neurogastroenterol Motil.* 2015 Jan 1;21(1):111-20.

153) Rohatgi S., Ahuja V., Makharia G., Rai T., Das P., Dattagupta S., Mishra V., Garg S. **VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial.** *BMJ Open Gastro*; 2015 Feb 9;2(1):e000018.

152) Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R, Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K. **The Probiotic VSL#3 has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence Following Surgery for Crohn's Disease.** *Clin Gastroenterol Hepatol.* 2015 May; 13(5):928-35.e2.

151) Valentini L., Pinto A., Bourdel-Marchasson I., Ostan R., Brigidi P., Turrone S., Hrelia S., Hrelia P., Bereswill S., Fischer A., Leoncini E., Malaguti M., Blanc-Bisson C., Durrieu J., Spazzafumo L., Buccolini F., Pryen F., Donini LM., Franceschi C., Lochs H. **Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people.** *Clin Nutr.* 2015 Aug; 34(4):593-602.

150) Mouli P., Benjamin J., Singh B., Mani K., Garg SK., Saraya A., Joshi YK. **Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy a non-inferiority randomized controlled trial.** *Hepatol Res.* 2015 Aug; 45(8):880-9.

149) Wong R., Yang C., Song C., Wong J., Ho K. **Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study.** *Dig Dis Sci.* 2015 Jan; 60(1):186-94.

- 148) Mariman R., Tielen F., Koning F., Nagelkerken L. **The Probiotic mixture VSL#3 dampens LPS- Induced Chemokine Expression in Human Dendritic Cells by Inhibition of STAT-1 Phosphorylation.** *Plos One* Dec 2014; 29;9(12):e115676.
- 147) Samanta A., Mandal A., Patra A., Mandal S., Roy S., Pradhan S., Das K., and Nandi D. **Impact of Probiotic supplementation on intestinal microflora of rat under environmental hypobaric pressure.** *Int.J.Curr.Microbiol.App.Sci* (2014) 3(8) pp. 282-291.
- 146) Sanaie S., Mameghani M., Hamishehkar H., Mojtahedzadeh M., Mahmoodpoor A. **Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial.** *J Res Med Sci.* 2014 ; 19(9): 827-833.
- 145) Distrutti E., O'Reilly J., McDonald C., Cipriani S., Renga B., Lynch M, Fiorucci S. **Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP.** *PLoS One.* 2014 Sep 9;9(9):e106503.
- 144) Mariman R., Kremer B., Koning F., Nagelkerken L. **The probiotic mixture VSL#3 mediates both pro- and anti-inflammatory responses in bone marrow-derived dendritic cells from C57BL/6 and BALB/c mice.** *Br J Nutr.* 2014 Oct 14;112(7):1088-97.
- 143) Dhiman R., Rana B., Agrawal S., Garg A., Chopra M., Thumburu K., Khattri A., Malhotra S., Duseja A., Chawla Y. **Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.** *Gastroenterology* 2014 Dec; 147:1327–1337.
- 142) Mar J, Nagalingam N, Song Y, Onizawa M, Lee JW, Lynch S. **Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition.** *Gut Microbes.* 2014 Jul 1;5(4):494-503.
- 141) Vicari E., La Vignera S., Castiglione R., Condorelli R., Vicari L., Aldo E Calogero. **Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3.** *Asian J Androl* 2014 Sep-Oct;16(5):735-9.
- 140) Isidro R., Bonilla F., Pagan H., Cruz M., Lopez P., Godoy L., Hernandez S., Loucil-Alicea R., Rivera-Amill V., Yamamura Y. Isidro A., Appleyard C. **The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner.** *J Clin Cell Immunol* 2014 Jun 20;5(3):1000227
- 139) Rashid S., Khodja N. Auger C., Alhosin M., Boehm N., Mammosser M., Schini-Kerth V. **Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System.** *Plos One* May 2014 May 15;9(5):e97458.
- 138) Rajkumar H., Mahmood N., Kumar M., Varikuti S., Challa H., Myakala S. **Effect of Probiotic (VSL#3) and Omega-3 on Lipid Profile, Insulin Sensitivity, Inflammatory Markers, and Gut Colonization in Overweight Adults: A Randomized, Controlled Trial.** *Mediators of Inflammation* 2014;2014:348959

- 137) Alisi A., Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., Giammaria P., Reali L., Anania F., Nobili V. **Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.** *Alimentary Pharmacology & Therapeutics* 2014 Jun;39(11):1276-85.
- 136) Rossi G, Pengo G, Caldin M, Palumbo Piccionello A, Steiner JM, Cohen ND, Jergens AE, Suchodolski JS. **Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease.** *PLoS One.* 2014 Apr 10;9(4):e94699
- 135) Rincón D., Vaquero J., Hernando A., Galindo E., Ripoll C., Puerto M., Salcedo M., Francés R., Matilla A., Catalina M., Clemente G., Such J., Bañares R. **Oral Probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites.** *Liver International* Nov; 2014 34(10):1504-12.
- 134) De Girolamo C. Rainaldi S., Bovenga F. Murzilli S. Moschetta A. **Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice.** *Cell Reports* 2014 Apr 10;7(1):12-8.
- 133) Rubio-del-Campo A., M. Coll-Marques J., Yebra M., Buesa J., Perez-Martinez G., Monedero V., Rodriguez-Diaz J. **Noroviral P-Particles as an In Vitro Model to Assess the Interactions of Noroviruses with Probiotics.** *Plos One* 2014 Feb 21;9(2):e89586.
- 132) Sang L., Chang B., Dai C, Gao N., Liu W.,Jiang M. **Heat-killed VSL#3 Ameliorates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis in Rats.** *Int. J. Mol. Sci.* 2014 Dec 19;15(1):15-28.
- 131) Lunia K., Sharma B., Sharma P., Sachdeva S., Srivastava S. **Probiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: a Randomized Controlled Trial.** *Clinical Gastroenterology and Hepatology* 2014 Jun;12(6):1003-8.e1.
- 129) Liang S., Webb T., Li z. **Probiotics Antigens Stimulate Hepatic NKT cells.** *Immunology* 2014 Feb;141(2):203-10.
- 130) Pellino G., Sciaudone G., Candilio G., Camerlingo A., Marcellinaro R., De Fatico S., Rocco F., Canonico S., Riegler G., Selvaggi F. **Early postoperative administration of probiotics versus placebo in elderly patients undergoing elective colorectal surgery: a double-blind randomized controlled trial.** *BMC Surgery* 2013, 13(Suppl 2):S57
- 128) Salim S.Y., Young P.Y., Lukowski C.M., Madsen K.L., Sis B., Churchill T.A., Khadaroo R.G. **VSL#3 probiotics provide protection against acute intestinal ischemia/perfusion injury.** *Beneficial Microbes* 2013 Dec 1;4(4):357-65.
- 127) Mameghani M., Sanaie S., Mahmoodpoor A., Hamishehkar H. **Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study).** *Pak J Med Sci* 2013;29(2):490-494.

- 126) Chang B., Sang L., Wang Y., Tong J., Zhang D., Wang B. **The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury.** *BMC Gastroenterology* 2013 Oct 20;13(1):1-1.
- 125) Sanaie S., Mameghani M., Mahmoodpoor A., Kamran S., Samad E. **Effect of a Probiotic Preparation (VSL#3) on Cardiovascular Risk Parameters in Critically-III Patients.** *Journal of Cardiovascular and Thoracic Research*, 2013, 5(2), 67-70.
- 124) Arthur J., Gharaibeh R., Uronis J., Perez-Chanona E., Sha W., Tomkovich S., Muhlbauer M., Fodor A., Jobin C. **VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer.** *Scientific Reports* 2013 Oct 8;3:2868.
- 123) Jayakumar S., Carbonneau M., Hotte N., Befus A., St. Laurent C., Owen R., McCarthy M., Madsen K., Bailey R., Ma M., Bain V., Rioux K., Tandon P. **VSL#3 probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis.** *Liver International*, 2013 Nov;33(10):1470-7.
- 122) Barletta B., Rossi G., Schiavi E., Butteroni C., Corinti Silvia, Boirivant M., Di Felice G. **Probiotic VSL#3-induced TGF- $\beta$  ameliorates food allergy inflammation in a mouse model of peanut sensitization through the induction of regulatory T cells in the gut mucosa.** *Mol. Nutr. Food Res.* 2013, 00, 1-12
- 121) Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. **Beneficial Metabolic Effects of a Probiotic via Butyrate-induced GLP-1 Hormone Secretion.** *J Biol Chem.* 2013 Aug 30;288(35):25088-97.
- 120) Ng S., Lam E., Lam T., Chan Y., Law W., Tse P., Kamm M., Sung J., Chan F., Wu J. **Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome.** *Journal of Gastroenterology and Hepatology* 2013 Oct;28(10):1624-31.
- 119) Distrutti E., Cipriani S., Mencarelli A., Renga B., Fiorucci S. **Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome.** *Plos One* 2013 May 15;8(5):e63893.
- 118) Gupta N., Kumar A., Sharma P., Garg V., Sharma B., Sarin S. **Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.** *Liver International* 2013 Sep;33(8):1148-57.
- 117) Selinger C.P., Bell A. Cairns A., Lockett M., Sebastian S., Haslam N. **Probiotic VSL#3 prevents probiotic – associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial.** *Journal of Hospital Infection* 2013 Jun;84(2):159-65.
- 116) Facchinetti F., Dante G., Pedretti I., Resasco P., Annessi E., Dodero D. **The role of oral probiotic for bacterial vaginosis in pregnant women. A pilot study.** *Minerva Ginecologica.* 2013 Apr;65(2):215-21.
- 115) Dharmani P., De Simone C., Chadee K. **The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor.** *Plos One* 2013;8(3):e58671.

- 114) Hörmannspurger G., Von Schillde M.A., Haller D. **Lactocepin as a protective microbial structure in the context of IBD.** *Gut Microbes.* 2013 Mar-Apr;4(2):152-7.
- 113) Klatt N., Canary L., et Al. **Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques.** *J Clin. Investigation.* 2013 Feb;123(2):903-7.
- 112) Dai C., Zheng CQ., Meng FJ., Zhou Z., Sang LX., Jiang M. **VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF- $\kappa$ B pathway in rat model of DSS-induced colitis.** *Mol Cell Biochem.* 2013 Feb;374(1-2):1-11.
- 111) Thang CL, Boye JI, Zhao X. **Low Doses of Allergen and Probiotic Supplementation Separately or in Combination Alleviate Allergic Reactions to Cow  $\beta$ -Lactoglobulin in Mice.** *J Nutr.* 2013 Feb;143(2):136-41.
- 110) Arslan H., Sarpinar aksu D., Terzi G., Nisbet C., **Therapeutic effects of probiotic bacteria in parvoviral enteritis in dogs.** *Revue Méd. Vét.* 2012 163, 2, 55-59.
- 109) Zhang H., Yu L., Yang W., Tang L., Lin Y., Wu H., Zhai B., Tan Y., Shan L., Liu Q., Chen H., Dai R., Qiu, He Y., Wang C., Zheng L., Qiong Li Y., Quan Wu F., Li Z., Yan H., Wang H. **Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats.** *Journal of Hepatology* 2012 Oct;57(4):803-12. (+ supplement data)
- 108) Dai C., Zhao DH., Jiang M. **VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways.** *International Journal of Molecular Medicine* 2012 Feb;29(2):202-8.
- 107) Vitali B., Cruciani F., Baldassarre M.E., Capursi T., Spisni E., Valerii M.C., Candela M., Turrone S., Brigidi P. **Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion.** *BMC Microbiology* 2012 Oct 18;12:236.
- 106) Mencarelli A., Cipriani S., Renga B., Bruno A., D'Amore C., Distrutti E., Fiorucci S. **VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.** *Plos one* 2012;7(9):e45425.
- 105) Lee J., Moon G., Kwon H., Jung W., Seo P., Baec T., Kim H. **Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis.** *Korean J Gastroenterol* 2012 Aug;60(2):94-101.
- 104) Campeau J.L., Salim S.Y. Albert E.J., Hotte N., Madsen K.L. **Intestinal epithelial cells modulate antigen-presenting cell responses to bacterial DNA.** *Infect. Immun.* 2012 Aug;80(8):2632-44.
- 103) Corridoni D., Pastorelli L., Mattioli B., Locovei S., Ishikawa D., Arseneau K., Chieppa M., Cominelli F., Pizarro T. **Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by TNF- dependent mechanism.** *Plos One* 2012;7(7):e42067.



- 102) Agrawal A., Sharma BC., Sharma P., Sarin SK. **Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy.** *American Journal of Gastroenterology* 2012 Jul;107(7):1043-50.
- 101) Stephens J.H. and Hewett P.J. **Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome.** *ANZ Journal of Surgery* 2012 Jun;82(6):420-7.
- 100) Rosania R., Minenna M., Giorgio F., Faciorusso A., De Francesco V., Hassan C., Panella C., Ierardi E. **Probiotic multistrain treatment may eradicate *Helicobacter pylori* from the stomach of dyspeptics : a placebo - controlled study.** *Inflammation & Allergy – Drug Targets* 2012 Jun;11(3):244-9.
- 99) Von Schillde M.A., Hörmannspenger G., Weiher M., Alpert C.A., Hahne H., Bäuerl C., Van Huynegem K., Steidler L., Hrnčir T., Pérez-Martinez G., Kuster B., Haller D. **Lactocepin secreted by *Lactobacillus* exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines.** *Cell Host & Microbe* 2012 Apr 19;11(4):387-96.
- 98) Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Hontecillas R. **Immunoregulatory mechanism underlying prevention of colitis – associated colorectal cancer by probiotic bacteria.** *Plos One* 2012;7(4):e34676.
- 97) Rehman A. et Al. **Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine.** *BMC Microbiology* 2012 Mar 27;12:47.
- 96) Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Carbo A., Shayhutdinov R., Jobin C., Arthur J., Corl B., Vogel H., Storr M., Hontecillas R. **Probiotic Bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR  $\gamma$  to suppress colitis.** *Plos One* 2012;7(2):e31238.
- 95) Dai C., Guandalini S., Zhao D.-H., Jiang M. **Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function.** *Molecular and cellular Biochemistry* 2012 Mar;362(1-2):43-53.
- 94) Gad M., Ravn P., Soborg D., Lund-Jensen K., Ouwehand A., Jensen S. **Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria.** *FEMS Immunol Med Microbiol.* 2011 Oct;63(1):93-107.
- 93) Tursi A., Elisei W., Brandimarte G., Giorgetti GM., Inchingolo C., Nenna R., Ierardi E. **Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis down-regulates after treatment.** *J Gastrointestin Liver Dis.* 2011 Dec;20(4):365-70.
- 92) Mariman R., Kremer B., Van Erk M., Lagerweij T., Koning F., Nagelkerken L. **Gene expression profiling identifies mechanism of protection to recurrent trinitrobenzene sulfuric acid colitis mediated by probiotics.** *Inflamm Bowel Dis.* 2012 Aug;18(8):1424-33.
- 91) Mittal Vibhu Vibhas, Sharma Barjesh Chander, Sharma Praveen, Sarin Shiv Kumar. **A randomized controlled trial comparing lactulose, probiotics and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.** *Eur J Gastroenterol Hepatol.* 2011 Aug;23(8):725-32.

- 90) Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C. **Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.** *Am J Physiol Gastrointest Liver Physiol.* 2011 Dec;301(6):G1004-13.
- 89) Ismail Al-Wahsh, Yan Wu, Michael Liebman. **Acute probiotics ingestion reduces gastrointestinal oxalate absorption in healthy subjects.** *Urol Res.* 2012 Jun;40(3):191-6.
- 88) Mencarelli A., Palladino G., Renga B., D'Amore C., Cipriani S., Distrutti E. and Fiorucci S. **Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation.** *PLoS One.* 2011;6(7):e22978.
- 87) Michail S. and Kenche H. **Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome.** *Probiotics Antimicrob Proteins.* 2011 Mar;3(1):1-7.
- 86) Angulo S., Danese S., Morales A., Llacuna L., Masamunt M.C., Pultz N., Cifone M.G., DeSimone C., Delgado S., Vila G., Panes D., Donskey C., Fernandez-Checa J.C., Fiocchi C. and Sans M. **Probiotics selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase.** *PLoS One.* 2011 Mar 9;6(3):e16953
- 85) Friederich P., Verschuur J., van Heumen B.W.H., Roelofs H.M.J., Berkhout M., Nagtegaal I.D., van Oijen M.G.H., van Krieken Johannes, Peters W.H.M. and Nagengast F.M. **Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis** *Int J Colorectal Dis.* 2011 May;26(5):575-82
- 84) Zaharoni H., Rimon E., Vardi H., Friger M., Bolotin A., Shahar DR. **Probiotics improve bowel movements in hospitalized elderly patients -The PROAGE study.** *J Nutr Health Aging.* 2011 Mar;15(3):215-20.
- 83) Schiavi E., Barletta B., Butteroni C., Corinti S., Boirivant M. e Di Felice G. **Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy.** *Allergy.* 2011 Apr;66(4):499-508.
- 82) Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, Appleyard CB, Jobin C. **Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis.** *Inflamm Bowel Dis.* 2011 Jan;17(1):289-97.
- 81) Aumeunier A., Grela F., Ramadan A., Pham Van L., Bardel E., Alcalá A., Jeannin P., Akira S., Bach J-F., Thieblemont N. **Systemic Toll-like Receptor Stimulation Suppresses Experimental Allergic Asthma and Autoimmune Diabetes in NOD Mice.** *PLoS One.* 2010 Jul 7;5(7):e11484.
- 80) Hörmannspenger G, Clavel T, Hoffmann M, Reiff C, Kelly D, Loh G, Blaut M, Hölzlwimmer G, Haller D. **Posttranslational Inhibition of Proinflammatory Chemokine Secretion in Intestinal Epithelial Cells: Implications for Specific IBD Indications.** *J Clin Gastroenterol.* 2010 Sep;44 Suppl 1:S10-5.
- 79) Tursi A., Brandimarte G., Papa A., Giglio A., Elisei W., Giorgetti GM, Forti G., Morini S., Hassan C., Pistoia MA., Modeo ME, Rodino S., D'Amico T., Sebkova L., Sacca N., Di Giulio E., Lizza F., Imeneo M., Larussa T., Di Rosa S., Annese V., Danese S. and Gasbarrini A. **Treatment of Relapsing**

**Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL # 3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study.** *Am J Gastroenterol.* 2010 Oct;105(10):2218-27.

78) Guandalini S., Magazzù G., Chiaro A., La Balestra V., Di Nardo G., Gopalan S., Sibal A., Romano C., Canani RB., Lionetti P., Setty M. **VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study.** *J Pediatr Gastroenterol Nutr.* 2010 Jul;51(1):24-30

77) Montalto M., Gallo A., Curigliano V., D'Onofrio F., Santoro L., Covino S., Dalvai S., Gasbarrini A. and Gasbarrini G. **The effects of a probiotic mixture on NSAID enteropathy: a randomized, double-blind, cross-over, placebo-controlled study.** *Aliment Pharmacol Ther.* 2010 Jul;32(2):209-14.

76) Ng S.C., Plamondon S., Kamm M.A., Hart A.L., Al-Hassi H.O., Guenther T., Stagg A.J. Knight S.C. **Immunosuppressive Effects via Human Intestinal Dendritic Cells of Probiotic Bacteria and Steroids in the Treatment of Acute Ulcerative Colitis.** *Inflamm Bowel Dis.* 2010 Aug;16(8):1286-98.

75) Okombo J. and Liebman M. **Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects.** *Urol Res.* 2010 Jun;38(3):169-78.

74) Frohmader TJ., Chaboyer WP., Robertson IK., Gowardman J. **Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial.** *Am J Crit Care.* 2010 May;19(3):e1-11.

73) Pagnini C., Saeed R., Bamias G., Arseneau KO., Pizarro TT., Cominelli F. **Probiotics promote gut health through stimulation of epithelial innate immunity.** *Proc Natl Acad Sci U S A.* 2010 Jan 5;107(1):454-9.

72) Turrone S., Vitali B., Candela M., Gionchetti P., Rizzello F., Campieri M., Brigidi P. **Antibiotics and probiotics in chronic pouchitis: A comparative proteomic approach.** *World J Gastroenterol.* 2010 Jan 7;16(1):30-41.

71) Visich K., Pluth Yeo T. **The prophylactic use of probiotics in the prevention of radiation therapy-induced diarrhea.** *Clin J Oncol Nurs.* 2010 Aug;14(4):467-73.

70) Reiff, C., Delday M., Rucklidge G., Reid M., Duncan G., Wohlgemuth S., Hörmannspurger G., Loh G., Blaut M. Collie-Duguid E., Haller D. and Kelly D. **Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease.** *Inflamm Bowel Dis.* 2009 Nov;15(11):1721-36.

69) Sood A., Midha V., Makharia GK., Ahuja V., Singal D., Goswami P. and Tandon RK. **The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.** *Clin Gastroenterol Hepatol.* 2009 Nov;7(11):1202-9, 1209.e1.

68) Wang X., O'Gorman M. R. G., Bu H.F., Koti V., Zuo X.-Li, and Tan X-D. **Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10J mice.** *J Nutr.* 2009 Aug;139(8):1595-602.

- 67) Tandon P., Moncrief K., Madsen K., Arrieta M.C., Owen R.J., Bain V.G., Wong W.W., Ma M.M. **Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study.** *Liver Int.* 2009 Aug;29(7):1110-5.
- 66) El-Atti S. Abd, Wasicek K., Mark S., Hegazi R. **Use of probiotics in the management of chemotherapy-induced diarrhea: a case study.** *JPEN J Parenter Enteral Nutr.* 2009 Sep-Oct;33(5):569-70.
- 65) Mastrangeli G., Corinti S., Butteroni C., Afferni C., Bonura A., Boirivant M., Colombo P., Di Felice G. **Effects of live and inactivated VSL#3 probiotic preparations in the modulation of *in vitro* and *in vivo* allergen-induced Th2 responses.** *Int Arch Allergy Immunol.* 2009;150(2):133-43.
- 64) Hörmannspenger G., Clavel T., Hoffmann M., Reiff C., Kelly D., Loh G., Blaut M, Hölzlwimmer G., Laschinger M., Haller D. **Post-translational Inhibition of IP-10 Secretion in IEC by Probiotic Bacteria: Impact on Chronic Inflammation.** *PLoS One.* 2009;4(2):e4365.
- 63) Mennigen R., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., Bruewer M. **Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis.** *Am J Physiol Gastrointest Liver Physiol.* 2009 May;296(5):G1140-9.
- 62) Esposito E., Iacono A., Bianco G., Autore G., Cuzzocrea S., Vajro P., Canini RB., Calignano A., Raso GM., Meli R. **Probiotics reduce the inflammatory response induced by a High-Fat Diet in the liver of young rats.** *J Nutr.* 2009 May;139(5):905-11.
- 61) Arslan H.H., Gulbahar M.Y., Yavuz O., Bozkurt A., Terzi G. **Effect of Different Probiotics in Indomethacin-Induced Inflammatory bowel disease in Rats.** *Dtsch Tierärztl Wochenschr* **116**, 11-18 (2009)
- 60) Velayudham A., Dolganiuc A., Ellis M., Petrasek J., Kodys K., Mandrekar P., Szabo G. **VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.** *Hepatology.* 2009 Mar;49(3):989-97.
- 59) Huynh HQ., deBruyn J., Guan L., Diaz H., Li M., Girgis S., Turner J., Fedorak R., Madsen K. **Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.** *Inflamm Bowel Dis.* 2009 May;15(5):760-8.
- 58) Miele E., Pascarella F., Giannetti E., Quaglietta L., Baldassano R., Staiano A. **Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.** *Am J Gastroenterol.* 2009 Feb;104(2):437-43.
- 57) Otte JM. Rudja MN., Brand S., Ilka W., Schmidt WE., Schmitz F. **Probiotics regulate the expression of COX-2 in intestinal epithelial cells.** *Nutr Cancer.* 2009;61(1):103-13.
- 56) Harding S.V., Fraser K.G., Wykes L.J. **Probiotics stimulate liver and plasma protein synthesis in piglets with dextran sulfate-induced colitis and macronutrient restriction.** *J Nutr.* 2008 Nov;138(11):2129-35.

- 55) Kotka M., Lieden A., Petterson S., Trinchieri V., Masci A., D'Amato M. **Solute carriers (SLC) in inflammatory bowel disease: a potential target of probiotics?** *J Clin Gastroenterol.* 2008 Sep;42 Suppl 3 Pt 1:S133-5.
- 54) Dubey AP., Rajeshwari K., Chakravarty A., Famularo G. **Use of VSL#3 in the treatment of rotavirus diarrhea in children: preliminary results.** *J Clin Gastroenterol.* 2008 Sep;42 Suppl 3 Pt 1:S126-9.
- 53) Ma X., Hua J., Li Z. **Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells.** *J Hepatol.* 2008 Nov;49(5):821-30.
- 52) Soo I., Madsen KL., Qassim T., Sydora BC., Sherbaniuk R., Cinque B., Di Marzio L., Cifone MG., De Simone C., Fedorak RN. **VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation.** *Can J Gastroenterol.* 2008 Mar;22(3):237-42.
- 51) Schlee M., Harder J., Köten B., Stange EF., Wehkamp J., Fellermann K. **Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2.** *Clin Exp Immunol.* 2008 Mar;151(3):528-35.
- 50) Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M **Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells.** *Inflamm Bowel Dis.* 2008 May;14(5):662-8.
- 49) Mc Nally A., BS, LTC George H. Cummings, Peter R. Mc Nally, DO, FACG, FACP **A case of recurrent pouchitis successfully managed with a Probiotic, VSL#3** *Visible Human Journal of Endoscopy* Vol. 6 Issue 1 (2007)
- 48) Fitzpatrick LR, Hertzog KL, Quatse AL, Koltun WA, Small JS, Vrana K **Effects of the probiotic formulation VSL#3 on colitis in weanling.** *J Pediatr Gastroenterol Nutr.* 2007 May;44(5):561-70.
- 47) Bowen JM, Stringer AM, Gibson RJ, Yeoh ASJ, Hannam S, Keefe DMK **VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss.** *Cancer Biol Ther.* 2007 Sep;6(9):1449-54.
- 46) Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Mang M, Churchill T, Madsen K **Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis** *Hepatology.* 2007 Sep;46(3):841-50.
- 45) Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F **Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.** *Int J Colorectal Dis.* 2007 Sep;22(9):1103-8.
- 44) Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G, Campieri M **High-dose probiotics for the treatment of active pouchitis** *Dis Colon Rectum.* 2007 Dec;50(12):2075-82
- 43) Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, Famularo **Use of probiotics for prevention of radiation-induced diarrhea** *World J Gastroenterol* 2007 Feb; 13(6):912-915

- 42) Alberda C, Gramlich L, Meddings J, Field C, McCargar L, Kutsogiannis D, Fedorak R, Madsen K. **Effects of probiotic therapy critically ill patients: a randomized, double-blind, placebo-controlled trial.** *Am J Clin Nutr.* 2007 Mar;85(3):816-23.
- 41) De Angelis M, Rizzello CG, Scala E, De Simone C, Farris GA, Turrini F, Gobbetti M. **Probiotic preparation has the capacity to hydrolyze proteins responsible for wheat allergy.** *J Food Prot.* 2007 Jan;70(1):135-44.
- 40) Caballero-Franco C, Keller K, De Simone C, Chadee K. **The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells.** *Am J Physiol Gastrointest Liver Physiol.* 2007 Jan;292(1):G315-22.
- 39) Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SHE, Schmidt-Ullrich R, Steinhoff U. **Proteasome-mediated degradation of I $\kappa$ B $\alpha$  and processing of p105 in Crohn's disease and ulcerative colitis.** *J Clin Invest.* 2006 Dec;116(12):3195-203.
- 38) Massi M, Ioan P, Budriesi R, Chiarini C, Vitali B, Lammers KM, Gionchetti P, Campieri M, Lembo A, Brigidi P. **Effects of probiotic bacteria on gastrointestinal motility in Guinea-pig isolated tissue.** *World J Gastroenterol.* 2006 Oct 7;12(37):5987-94.
- 37) Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, Gionchetti P, Schrezenmeir J, Foelsch UR, Schreiber S, Campieri M. **Lactobacilli, bifidobacteria and E. coli nisse induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells.** *World J Gastroenterol* 2006 Oct 7;12(37):5978-86.
- 36) Ewaschuk JB, Walker JW, Diaz H, Madsen KL. **Bioproduction of conjugated linoleic Acid by probiotic bacteria occurs in vitro and in vivo in mice.** *J Nutr.* 2006 Jun;136(6):1483-7.
- 35) Kuehbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Shreiber S. **Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.** *Gut.* 2006 Jun;55(6):833-41.
- 34) Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C. **The VSL#3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice.** *J Nutr.* 2005 Dec;135(12):2753-61.
- 33) Linsalata M, Russo F, Berloco P, Valentini AM, Caruso ML, De Simone C, Barone M, Polimeno L, Di Leo A. **Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats.** *In Vivo.* 2005 Nov-Dec;19(6):989-95.
- 32) De Angelis M, Rizzello CG, Fasano A, Clemente MG, De Simone C, Silano M, De Vincenzi M, Losito I, Gobbetti M. **VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue.** *Biochim Biophys Acta.* 2006 Jan;1762(1):80-93.
- 31) Karimi O, Pena AS, van Bodegraven AA. **Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: A pilot study.** *Drugs Today (Barc).* 2005 Jul;41(7):453-9.
- 30) Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria M V, De Simone C, Del Vecchio Blanco C. **Beneficial effects of a probiotic VSL#3 on Parameters of liver dysfunction in chronic liver disease.** *J Clin Gastroenterol.* 2005 Jul;39(6):540-3.

- 29) Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant M, Dotta F. **Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse.** *Diabetologia*. 2005 Aug;48(8):1565-75.
- 28) Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G & Zinsmeister AR. **A randomized controlled trial of probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating.** *Neurogastroenterol Motil*. 2005 Oct;17(5):687-96.
- 27) Tursi A., Brandimante G, Giorgetti GM, Elisei M. **Beclometasone Dipropionate Plus VSL#3 for the Treatment of Mild to Moderate Diverticular Colitis: An Open Pilot Study.** *J Clin Gastroenterol*. 2005 Aug;39(7):644-5.
- 26) Bibiloni R., Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, DeSimone C, Sartor RB. **VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis.** *Am J Gastroenterol*. 2005 Jul;100(7):1539-46.
- 25) Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. **Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells.** *J Immunol*. 2005 Mar 15;174(6):3237-46.
- 24) Tursi A., Brandimarte G, Giorgetti GM, Forti G, Mondeo ME, Gigliobianco A. **Low dose balsalazide plus a high potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild to moderate ulcerative colitis.** *Med Sci Monit*. 2004 Nov;10(11):PI126-31.
- 23) Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Yun Tao, De Simone C, Chang EB. **Probiotics inhibit nuclear factor kB and induce heat shock proteins in colonic epithelial cells through Proteasome inhibition.** *Gastroenterology*. 2004 Nov;127(5):1474-87.
- 22) Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ. **Modulation of human dendritic cell phenotype and function by probiotic bacteria.** *Gut*. 2004 Nov;53(11):1602-9.
- 21) Drakes M, Blanchard T, Czinn S. **Bacterial probiotic modulation of dendritic cells.** *Infect Immun*. 2004 Jun;72(6):3299-309.
- 20) Jijon H, Backer J, Diaz H, Yeung H, Thiel D, Mc Kaigney C, De Simone C, Madsen K. **DNA from probiotic bacteria modulates murine and human epithelial and immune function.** *Gastroenterology*. 2004 May;126(5):1358-73.
- 19) Otte JM, Podolsky DK. **Functional modulation of enterocytes by gram-positive and gram-negative microorganisms.** *Am J Physiol Gastrointest Liver Physiol*. 2004 Apr;286(4):G613-26.
- 18) Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E. **Toll-Like Receptor 9 Signaling Mediates the Anti-inflammatory Effects of Probiotics in Murine Experimental Colitis.** *Gastroenterology*. 2004 Feb;126(2):520-8.

- 17) Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. **Once Daily High Dose Probiotic Therapy (VSL#3) for Maintaining Remission in Recurrent or Refractory Pouchitis.** *Gut.* 2004 Jan;53(1):108-14.
- 16) Lammers KM, Brigidi P, Vitali B, Gionchetti P, Rizzello F, Caramelli E, Matteuzzi D, Campieri M. **Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells.** *FEMS Immunol Med Microbiol.* 2003 Sep 22;38(2):165-72.
- 15) Vitali B., Candela M., Matteuzzi D., Brigidi P., **Quantitative detection of probiotic Bifidobacterium strains in bacterial mixtures by using real-time PCR.** *Syst Appl Microbiol.* 2003 Jun;26(2):269-76.
- 14) Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. **Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.** *Gastroenterology.* 2003 May;124(5):1202-9.
- 13) Kim HJ, Camilleri M, Mc Kinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. **A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.** *Aliment Pharmacol Ther.* 2003 Apr 1;17(7):895-904.
- 12) Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, De Simone C, Song X, Diehl AM. **Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.** *Hepatology.* 2003 Feb;37(2):343-50.
- 11) Brigidi P, Swennen E, Vitali B, Rossi M, Matteuzzi D. **PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption.** *Int J Food Microbiol.* 2003 Mar 25;81(3):203-9.
- 10) Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, Campieri M, Morgenstern S, Rachmilewitz D. **Variable response to probiotics in two models of experimental colitis in rats.** *Inflamm Bowel Dis.* 2002 Nov;8(6):399-406.
- 9) Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C. **Prophylaxis of diarrhoea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience.** *Dig Liver Dis.* 2002 Sep;34 Suppl 2:S84-6.
- 8) Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C. **Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation.** *Am J Gastroenterol.* Aug;97(8):2150-2.
- 7) Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm M, Brigidi P, Gionchetti P, Campieri M. **Effect of probiotic strains on interleukin 8 production by HT29/19A cells.** *Am J Gastroenterol.* 2002 May;97(5):1182-6.
- 6) Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. **Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea.** *Res Microbiol.* 2001 Oct;152(8):735-41.



- 5) Madsen K, Cornish A, Soper P, Mc Kaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. **Probiotic bacteria enhance murine and human intestinal epithelial barrier function.** *Gastroenterology*. 2001 Sep;121(3):580-91.
- 4) Ulisse S, Gionchetti P, D'Alo` S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C. **Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.** *Am J Gastroenterol*. 2001 Sep;96(9):2691-9.
- 3) Brigidi P, Vitali B, Swennen E, Altomare L, Rossi M, Matteuzzi D. **Specific detection of bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction.** *Syst Appl Microbiol*. 2000 Oct;23(3):391-9.
- 2) Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. **Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.** *Gastroenterology*. 2000 Aug;119(2):305-9.
- 1) Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M, **Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.** *Aliment Pharmacol Ther*. 1999 Aug;13(8):1103-8.